May Day activists cheer state immigration laws

SALEM, Ore. (AP) — As Congress debates the first national immigration overhaul in decades, a state-level push advancing rights for people in the U.S. illegally has picked up momentum across the country.

Courtesy of Yahoo News

Sanofi first-quarter misses forecasts on patent losses, forex

Sanofi first-quarter misses forecasts on patent losses, forex

By Elena Berton PARIS (Reuters) - Sanofi reported lower-than-expected first-quarter earnings on Thursday as the effects of last year's patent losses and foreign exchange headwinds crimped growth from diabetes drugs, vaccines and rare disease unit Genzyme. But the French drugmaker said it expected to return to growth in the second half of the year and confirmed that annual profit would be flat to 5 percent lower than in 2012 at constant exchange rates. "We are in the last quarter of the patent cliff ... ...

Source: news.yahoo.com

Natural Ethnic Skin Care: A True Perspective

Natural Ethnic Skin Care: A True Perspective
Long overdue is the fact that there are very few natural ethnic skin care products in the mainstream cosmetics industry to address skin of color properly. Read on to discover more.
Source: EzineArticles.com

Mom Slammed by Superstorm Sandy, Then Grim Diagnosis

Mom Slammed by Superstorm Sandy, Then Grim Diagnosis
Devorah Schochet has faced one tragedy after another: hurricane damage, a daughter with spinal tumors and now a terminal illness. The family is hoping an organization or home repair show can help them modify their damaged home to become handicapped-accessible.        
Source: abcnews.go.com

U.S. launch of Novo's new insulin faces long delay

U.S. launch of Novo's new insulin faces long delay
By Mette Fraende and Shida Chayesteh COPENHAGEN (Reuters) - Denmark's Novo Nordisk could see the U.S. launch of its biggest drug hope, a new long-acting insulin, delayed until 2018 while it conducts more tests to satisfy regulators, it said on Wednesday. The world's biggest insulin producer was dealt a major blow in February when the U.S. Food and Drug Administration (FDA) refused to approve the drug, called Tresiba, and instead asked for extra tests to assess potential heart risks. ...
Source: news.yahoo.com